Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Longbio Pharma

Clinicaltrial registered18 Nov 2026

Longbio Pharma

18 Nov 2026: Trial registered · A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
18 Nov 2026
Title
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
Conditions
Chronic Spontaneous Urticaria (CSU)
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Countries
China
Country
China
Reference
NCT07946913
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Longbio Pharma

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.